Compass Therapeutics, Inc. develops clinical-stage, oncology-focused antibody therapeutics targeting angiogenesis, immune activation and tumor-driven immunosuppression. News about CMPX centers on its antibody pipeline, including tovecimig, a DLL4 x VEGF-A bispecific antibody studied with paclitaxel in biliary tract cancer, and earlier-stage programs such as CTX-8371, CTX-10726 and CTX-471.
Recurring updates cover clinical trial results, FDA-related regulatory designations and interactions, medical-meeting presentations, pipeline expansion, financial results, cash resources, leadership changes and equity inducement grants under Nasdaq rules.
Compass Therapeutics, Inc. (OTCQB: CMPX) announced the participation of CEO Thomas Schuetz in two virtual investor conferences: the H.C. Wainwright Global Life Sciences Conference on March 9-10, 2021, and the 33rd Annual Roth Conference on March 15-17, 2021. The H.C. Wainwright presentation will be available on demand, while a live panel discussion on bispecific antibodies will occur on March 16, 2021. Compass Therapeutics is focused on developing proprietary antibody therapeutics targeting solid tumors and hematological malignancies, including its lead candidate, CTX-471, in a Phase 1b study.
Compass Therapeutics, Inc. (OTCQB: CMPX) has announced that its common stock shares have been approved for trading on the OTCQB Venture Market in the U.S., effective March 5, 2021. The company specializes in developing proprietary antibody therapeutics aimed at treating solid tumors and hematological malignancies. Its lead candidate, CTX-471, is currently in a Phase 1 clinical study targeting patients who have relapsed after PD-1/PD-L1 treatment. The company operates from Boston, MA, and focuses on engaging the immune system through its innovative platforms.